These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 27996251)

  • 1. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
    Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
    Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time.
    Rafols L; Josa D; Aguilà D; Barrios LA; Roubeau O; Cirera J; Soto-Cerrato V; Pérez-Tomás R; Martínez M; Grabulosa A; Gamez P
    Inorg Chem; 2021 Jun; 60(11):7974-7990. PubMed ID: 33979132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N- and S-donor leaving groups in triazole-based ruthena(ii)cycles: potent anticancer activity, selective activation, and mode of action studies.
    Riedl CA; Hejl M; Klose MHM; Roller A; Jakupec MA; Kandioller W; Keppler BK
    Dalton Trans; 2018 Mar; 47(13):4625-4638. PubMed ID: 29520401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Cytotoxic Ruthenium(II)-Arene Complexes from Bulky 1-Pyrenylphosphane Ligands.
    Brissos RF; Clavero P; Gallen A; Grabulosa A; Barrios LA; Caballero AB; Korrodi-Gregório L; Pérez-Tomás R; Muller G; Soto-Cerrato V; Gamez P
    Inorg Chem; 2018 Dec; 57(23):14786-14797. PubMed ID: 30444630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triazole-Based Half-Sandwich Ruthenium(II) Compounds: From
    Lenis-Rojas OA; Cabral R; Carvalho B; Friães S; Roma-Rodrigues C; Fernández JAA; Vila SF; Sanchez L; Gomes CSB; Fernandes AR; Royo B
    Inorg Chem; 2021 Jun; 60(11):8011-8026. PubMed ID: 33973771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.
    Marloye M; Inam H; Moore CJ; Debaille V; Pritchard JR; Gelbcke M; Meyer F; Dufrasne F; Berger G
    J Biol Inorg Chem; 2021 Aug; 26(5):535-549. PubMed ID: 34173882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
    Meier SM; Novak M; Kandioller W; Jakupec MA; Arion VB; Metzler-Nolte N; Keppler BK; Hartinger CG
    Chemistry; 2013 Jul; 19(28):9297-307. PubMed ID: 23712572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
    Büchel GE; Gavriluta A; Novak M; Meier SM; Jakupec MA; Cuzan O; Turta C; Tommasino JB; Jeanneau E; Novitchi G; Luneau D; Arion VB
    Inorg Chem; 2013 Jun; 52(11):6273-85. PubMed ID: 23659478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
    Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
    J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
    Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
    Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
    Reddy VG; Bonam SR; Reddy TS; Akunuri R; Naidu VGM; Nayak VL; Bhargava SK; Kumar HMS; Srihari P; Kamal A
    Eur J Med Chem; 2018 Jan; 144():595-611. PubMed ID: 29289884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
    Novak MS; Büchel GE; Keppler BK; Jakupec MA
    J Biol Inorg Chem; 2016 Jun; 21(3):347-56. PubMed ID: 26961253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines.
    Ginzinger W; Mühlgassner G; Arion VB; Jakupec MA; Roller A; Galanski MS; Reithofer M; Berger W; Keppler BK
    J Med Chem; 2012 Apr; 55(7):3398-413. PubMed ID: 22417128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ru
    Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
    Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruthenium(II) and osmium(II) 1,2,3-triazolylidene organometallics: a preliminary investigation into the biological activity of 'click' carbene complexes.
    Kilpin KJ; Crot S; Riedel T; Kitchen JA; Dyson PJ
    Dalton Trans; 2014 Jan; 43(3):1443-8. PubMed ID: 24201979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.
    Hildebrandt J; Häfner N; Kritsch D; Görls H; Dürst M; Runnebaum IB; Weigand W
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
    de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
    Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action.
    Pavlović M; Nikolić S; Gligorijević N; Dojčinović B; Aranđelović S; Grgurić-Šipka S; Radulović S
    J Biol Inorg Chem; 2019 Mar; 24(2):297-310. PubMed ID: 30762123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.